Plant · Scientific monograph
Valeriana officinalis
Valerian
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: CNS Depression Research, Stress & Anxiety Research, Sleep Research, GABAergic
Research overview
Historical use
Valeriana officinalis has been used as a sedative and anxiolytic since antiquity — Hippocrates described its properties and Galen prescribed it for insomnia. The name derives from the Latin 'valere' (to be well). Widely used throughout medieval Europe for nervous disorders, it was listed in the US Pharmacopoeia until 1942 and remains among the most commonly used herbal medicinal products in primary care globally [8].
Modern research context
Valeriana officinalis demonstrates evidence-based efficacy for insomnia and anxiety through multi-organ, multi-target mechanisms [1]. A 2026 comprehensive review confirms its role as a GABAergic, serotonergic, and adenosinergic modulator with documented clinical benefits for insomnia [5]. A randomised controlled trial demonstrated significant reduction in anxiety scores compared to placebo in patients undergoing tooth extraction [4]. Valerian is the most commonly cited herbal product in Brazilian primary care settings, though clinical users face risk of herb-drug interactions [8].
Adverse effects
Generally well tolerated. Paradoxical stimulant effects reported in some individuals, particularly children. Morning grogginess ('hangover effect') at higher doses. Rare: hepatotoxicity in case reports. Potential for additive CNS depression with concomitant sedative agents [2]. Abrupt discontinuation after prolonged use may cause withdrawal symptoms analogous to benzodiazepine discontinuation.
Contraindications
Contraindicated with benzodiazepines, barbiturates, and opioids due to additive CNS depression [2]. Avoid with CYP3A4-metabolised drugs with narrow therapeutic indices — direct CYP3A inhibition and P-glycoprotein modulation documented [3]. Avoid with alcohol. Caution in patients with hepatic impairment. Do not use in pregnancy or lactation.
Clinical and phytochemical data
Used part
Root and rhizome (dried or as hydroethanolic extract)
Primary active compounds
Valerenic acid and derivatives (sesquiterpenes)
Isovaleric acid
Valepotriates (iridoid esters: valtrate, isovaltrate)
Lignans (hydroxypinoresinol)
Flavonoids (linarin, hesperidin)
GABA and glutamine (free amino acids)
Mechanism of action
Valerenic acid and its derivatives are direct partial agonists at the GABA-A receptor (beta-subunit), potentiating inhibitory neurotransmission and producing anxiolytic and sedative effects without full benzodiazepine-receptor occupancy [1]. The extract modulates serotonin (5-HT5a) receptor binding and inhibits synaptosomal serotonin reuptake, contributing to mood-stabilising effects [6]. Valepotriates act as adenosine receptor ligands and modulate adenosine A1 receptors, promoting sleep through adenosinergic pathways [5]. Multi-organ actions include gastrointestinal spasmolysis via smooth muscle relaxation and autonomic nervous system dampening [1].
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Valerenic acid is the primary monitored pharmacokinetic marker. Valepotriates are highly unstable and largely degrade in the GI tract prior to systemic absorption; their in vivo activity may be mediated by degradation products (baldrinals). Oral bioavailability of valerenic acid has not been formally characterised in a published human PK study.
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Valerenic acid is lipophilic and expected to cross the blood-brain barrier, consistent with the observed central sedative and anxiolytic effects [1]. Protein binding and volume of distribution in humans are not established.
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Valeriana officinalis extract inhibits CYP3A4 activity and modulates P-glycoprotein efflux transporter function, as demonstrated in direct experimental studies of intestinal metabolism of midazolam [3]. This interaction is clinically significant for drugs with high first-pass CYP3A4 metabolism.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Elimination routes and half-life of valerenic acid and active metabolites in humans are not established in published clinical pharmacokinetic studies.
Safety and interactions
Drug interactions
CYP3A4 substrates and P-glycoprotein substrates: Valeriana officinalis extracts directly inhibit intestinal CYP3A4 metabolism and modulate P-glycoprotein, demonstrated by inhibition of midazolam intestinal metabolism in vitro [3]; drugs with narrow therapeutic windows metabolised by CYP3A4 (e.g. cyclosporine, tacrolimus, statins, benzodiazepines) require monitoring. CNS depressants (benzodiazepines, barbiturates, opioids, alcohol): Additive sedation through shared GABAergic mechanism is documented; combination increases risk of excessive CNS depression [2]. Antidepressants: Complex pharmacokinetic and pharmacodynamic interactions possible through serotonergic and CYP450 pathways [6]. High potential for herb-drug interactions documented in primary care surveillance data [8].
Toxicity
Valeriana officinalis is well tolerated at standard doses in available clinical studies; adverse effects are generally mild. Rare case reports of hepatotoxicity exist, likely attributable to valepotriate alkylating activity at high doses. Paradoxical excitation reported particularly in paediatric populations [6]. No established LD50 in humans. Abrupt discontinuation after prolonged use may produce a withdrawal syndrome. Long-term use beyond 4–6 weeks has not been systematically evaluated in controlled trials; long-term safety data are accordingly limited.
Special precautions
Pregnancy
Valepotriates are cytotoxic and potentially mutagenic in vitro. Avoid during pregnancy.
Lactation
Excretion in breast milk unknown. Avoid during lactation due to insufficient safety data.
Hepatic impairment
Rare hepatotoxicity cases documented. CYP3A4 inhibition [3] will be amplified in hepatic impairment. Contraindicated in active hepatic disease.
Renal impairment
No formal studies in renal impairment. Use with caution; renal excretion of conjugated metabolites expected.
Sources and references
- [1] - Yang S, Zhang H, Chen L et al., "Valeriana species and insomnia: multi-organ mechanisms and translational perspectives", Pharmaceutical Biology, 2026, PMID: 41995686
- [2] - Caus MN, Lupoae M, Chitescu CL, "Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action", Pharmaceuticals, 2026, PMID: 41901246
- [3] - Nascimento ML, do Nascimento SB, Lima ESP et al., "Evaluation of Extracts Containing Valeriana officinalis and Piper methysticum on Cytochrome P450 3A and P-Glycoprotein", Planta Medica, 2024, PMID: 39013429
- [4] - Velasquez ACA, Tsuji M, Dos Santos Cordeiro L et al., "Effects of Passiflora incarnata and Valeriana officinalis in the control of anxiety due to tooth extraction: a randomized controlled clinical trial", Oral and Maxillofacial Surgery, 2024, PMID: 38743126
- [5] - Ma D, Yang H, Zhao M et al., "Multi-target regulatory mechanisms of natural products for insomnia", Frontiers in Pharmacology, 2026, PMID: 41613780
- [6] - Bertollo AG, Spohr L, Bearzi AE et al., "Medicinal Plants for Major Depressive Disorder", Brain Sciences, 2026, PMID: 41750223
- [7] - Oliveira MVB, Garguerra JA, Lamas CB et al., "Unraveling the Effects of Melissa officinalis on Cognition and Sleep Quality", International Journal of Molecular Sciences, 2025, PMID: 41226605
- [8] - Cota BB, Alves JC, de Caux AA et al., "Use of herbal medicinal products in primary health care in Brazil", Einstein, 2024, PMID: 39536211